Sexually Transmitted infections (STIs) such as syphilis, gonorrhea, herpes and chlamydia are a major health concern in the United States.
Ideally, treatment for STIs would include testing sexual partners of infected persons, and treating them if they're infected as well. However, this can be difficult to accomplish. "Empiric or expedited partner treatment is gaining popularity," says Gianna Zuccotti, MD, MPH, deputy editor of The Medical Letter on Drugs and Therapeutics, a nonprofit newsletter that critically appraises drugs. "This approach means that the physician gives medication to the infected person to give to their partner, rather than requiring the partner to come in. Expedited partner treatment is increasingly used by physicians who care for people with STIs. It means you can't do partner counseling or HIV testing, but it has the advantage of increasing treatment access for people who might not come in on their own."
GONORRHEA AND SYPHILIS The number of gonorrhea cases in the U.S. currently is at an all-time low. The number varies dramatically among the states, ranging from 265 per 100,000 in Louisiana, to 5 per 100,000 in Idaho. Single doses of oral antibiotics are highly effective for gonorrhea, but untreated cases can lead to epididymitis in men, pelvic inflammatory disease and ectopic pregnancy in women, and infertility in both men and women.
GENITAL HERPES Genital herpes is a very common viral infection, causing recurrent clusters of blisters or bumps in the genital area. Many people carry the infection without any symptoms, and can unknowingly transmit the virus to a sexual partner. Between the late 1970s and the early 1990s, the number of Americans with genital herpes increased 30%. Currently about 45 million people have genital herpes; that's one out of every five adolescents and adults. Although the infection can stay in the body indefinitely, the number of outbreaks tends to decrease over time.
The severity and duration of herpes symptoms and the frequency of attacks can be reduced by antiviral agents such as Zovirax (acyclovir), Famvir (famciclovir), and Valtrex (valacyclovir). These medicines are taken orally for 7 to 10 days to shorten the initial herpes outbreak, and can be used in lower doses to prevent or suppress recurrences. "Some people keep the medicine on hand and start treatment when they feel the first signs of an outbreak," Dr. Zuccotti says.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Lack of Diversity in Clinical Trials Hurts Research, and Costs Billions | AHA Scientific Sessions
November 12th 2023Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.
Read More
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Lack of Diversity in Clinical Trials Hurts Research, and Costs Billions | AHA Scientific Sessions
November 12th 2023Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.
Read More
2 Commerce Drive
Cranbury, NJ 08512